Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells

Hematology

Volumn 12, Issue 6, 2007, Pages 497-503

  Baran, Yusuf ^a,b   Ural, Ali Ugur ^b   Gunduz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib mesylate; Meg 01 cell line; Multidrug resistance

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; PROTEIN BAX; RNA;

APOPTOSIS; ARTICLE; BINDING SITE; CELL CYCLE; CELL INTERACTION; CELL LINE; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 35748981505     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701384179     Document Type: Article

References (28)

1. Druker, BJ (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med, 8, pp. 14-18.
2. Kantarjian, H., Dixon, D., Keating, MJ, Talpaz, M., Walters, RS, McCredie, KB and Freireich, EJ (1988) Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer, 61, pp. 1441-1446.
3. Ramadevi, N., DPhil, B. and Kapil, B. (2002) Mechanisms of resistance to imatinib mesylate in BCR/ABL positive leukemias. Curr Opin Onc, 14, pp. 616-620.
4. Vigneri, P. and Wang, JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR/ABL tyrosine kinase. Nat Med, 7, pp. 228-234.
5. Sawyers, CL (1999) Chronic myeloid leukemia. N Engl J Med, 340, pp. 1330-1340.
6. Savage, DG and Antham, KH (2002) Imatinib mesylate: A new oral targeted therapy. N Eng J Med, 346, pp. 683-693.
7. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, BJ and Lydon, NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 56, pp. 100-104.
8. Schindler, T., Bornmann, W., Pellicena, P., Miller, WT, Clarkson, B. and Kuriyan, J. (2000) Structural mechanism for STI571 inhibition of abelson tyrosine kinase. Science, 289, pp. 1938-1942.
9. Gambacorti-Passerini, C., Gunby, RH, Piazza, R., Galietta, A., Rostagno, R. and Scapozza, L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncol, 4, pp. 75-85.
10. Hegedus, T., Orifi, L., Seprodi, A., Varadi, A., Sarkadi, B. and Keri, G. (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochem Biophys Acta, 1587, pp. 318-325.
11. Walz, C. and Sattler, M. (2006) Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol, 57, pp. 145-164.
12. Deininger, M. (2005) Resistance to imatinib: Mechanisms and management. J Natl Compr Canc Netw, 3, pp. 757-768.
13. Litman, T., Druley, TE, Stein, WD and Bates, SE (2001) From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci, 58, pp. 931-959.
14. Dean, M., Hamon, Y. and Chimini, G. (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 42, pp. 1007-1017.
15. Baran, Y., Gündüz, Y. and Ural, AU (2006) Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol, 28, pp. 163-165.
16. Ogretmen, B., Schady, D., Usta, J., Wood, R., Kraveka, JM, Luberto, C., Birbes, H., Hannun, YA and Obeid, LM (2001) Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem, 276, pp. 24901-24910.
17. Koybasi, S., Senkal, CE, Sundararaj, K., Spassieva, S., Bielawski, J., Osta, W., Day, TA, Jiang, JC, Jazwinski, SM, Hannun, YA, Obeid, LM and Ogretmen, B. (2004) J Biol Chem, 279, pp. 44311-44319.
18. Mahon, FX, Deininger, MW, Schultheis, B., Chabrol, J., Reiffers, J., Goldman, JM and Melo, JV (2000) Selection and characterization of BCR/ ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood, 96, pp. 1070-1079.
19. Sultan, I., Senkal, CE, Ponnusamy, S., Bielawski, J., Szulc, Z., Bielawska, A., Hannun, YA and Ogretmen, B. (2006) Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function. Biochem J, 393, pp. 513-521.
20. Wiesberg, E. and Griffin, JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95, pp. 3498-3505.
21. Gorre, ME, Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, PN and Sawyers, CL (2003) Clinical resistance to STI571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science, 293, pp. 876-880.
22. Reed, JC (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol, 5, pp. 541-546.
23. Reed, JC, Miyashita, T., Takayama, S., Wang, HG, Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S. and Hanada, M. (1996) Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem, 60, pp. 23-32.
24. Dai, Y., Rahmani, M., Corey, SJ, Dent, P. and Grant, S. (2004) A BCR/ ABL-independent, Lyn-dependent form of Imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem, 279, pp. 34227-34239.
25. Salomoni, P., Condorelli, F., Sweeney, SM and Calabretta, B. (2000) Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood, 96, pp. 676-684.
26. Horita, M., Andreu, EJ, Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F. and Fernandez-Luna, JL (2002) Blockade of the BCR/ABL kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med, 191, pp. 977-984.
27. Zamzami, N., Brenner, C., Marzo, I., Susin, SA and Kroemer, G. (1998) Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene, 16, pp. 2265-2282.
28. Amarante-Mendes, GP, McGahon, AJ, Nishioka, WK, Afar, DE, Witte, ON and Green, DR (1998) Bcl-2-independent BCR/ABL-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL. Oncogene, 16, pp. 1383-1390.